USA flag logo/image

An Official Website of the United States Government

Development of New Production Technologies for Humanized Antibodies

Award Information

Agency:
Department of Defense
Branch:
Army
Award ID:
68418
Program Year/Program:
2004 / STTR
Agency Tracking Number:
A045-006-0246
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ALDER BIOPHARMACEUTICALS, INC.
21823 30th Dr SE Botthell, WA 98021
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Development of New Production Technologies for Humanized Antibodies
Agency / Branch: DOD / ARMY
Contract: W911NF-04-C-0093
Award Amount: $100,000.00
 

Abstract:

Humanized antibodies currently are produced through mammalian cell culture methods that require extensive resources, in particular, choosing the manufacturing cell line and the need for highly specialized cell growth facilities. These limitations have highlighted the need for new and more innovative ways for antibody production. Yeast heterologous protein expression systems have long been viewed as efficient and high yielding alternatives for mammalian cell line production. Yeast is able to deal with important folding and export issues that are unique to proteins found in higher eukaryotes, makes use of inexpensive media, has much greater routine commercialization, and enables significant reduction in cost and time for production. Antibody expression in this host provides an excellent solution for more efficient and expanded application of this class of therapeutics. In the case of antibodies, correct glycosylation was viewed a required feature. However, recent studies have questioned this requirement. Aglycosylated antibodies have been described to have comparable half-lives and retain function when the post-translational modification is eliminated. It is in this light that our proposal focuses on the use of Pichia pastoris as a new host for full-length antibody expression building on the extensive success this system has had for the production of therapeutic proteins.

Principal Investigator:

John Latham
Chief Scientific Officer, Founder
4255272703
latham@alderbio.com

Business Contact:

John Latham
Chief Scientific Officer, Founder
4255272703
latham@alderbio.com
Small Business Information at Submission:

ALDER BIOPHARMACEUTICALS, INC.
21823 30th Dr SE Botthell, WA 98021

EIN/Tax ID: 900134860
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
Keck Graduatate Institute
535 Watson Dr.
Claremont, CA 91711
Contact: Brian Aufderheide
Contact Phone: (909) 607-0398
RI Type: Nonprofit college or university